Profile data is unavailable for this security.
About the company
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
- Revenue in USD (TTM)88.04m
- Net income in USD-784.96m
- Incorporated1997
- Employees673.00
- LocationCytokinetics Inc350 Oyster Point BoulevardSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 624-3000
- Fax+1 (650) 624-3010
- Websitehttps://cytokinetics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunovant Inc | 0.00 | -464.20m | 5.44bn | 362.00 | -- | 5.51 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Protagonist Therapeutics Inc | 46.02m | -130.15m | 5.83bn | 132.00 | -- | 9.29 | -- | 126.60 | -2.04 | -2.04 | 0.7239 | 9.82 | 0.0651 | -- | 12.10 | 348,606.10 | -18.42 | -8.51 | -19.72 | -9.31 | -- | -- | -282.83 | -31.44 | -- | -- | 0.00 | -- | -89.41 | 9.96 | -147.29 | -- | 27.55 | -- |
| Cogent Biosciences Inc | 0.00 | -277.80m | 6.04bn | 258.00 | -- | 10.96 | -- | -- | -2.15 | -2.15 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -51.99 | -55.96 | -57.41 | -62.16 | -- | -- | -- | -- | -- | -- | 0.2594 | -- | -- | -- | -37.96 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -64.60m | 6.30bn | 25.00 | -- | 8.57 | -- | -- | -1.93 | -1.93 | 0.00 | 19.59 | 0.00 | -- | -- | -- | -13.85 | -23.54 | -13.94 | -24.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -114.73 | -- | -- | -- |
| Arcellx Inc | 22.29m | -228.93m | 6.67bn | 209.00 | -- | 16.42 | -- | 299.27 | -4.06 | -4.06 | 0.3945 | 6.95 | 0.0339 | -- | 7.31 | 106,631.60 | -34.81 | -28.60 | -42.17 | -34.05 | -- | -- | -1,027.26 | -274.64 | -- | -- | 0.00 | -- | -79.35 | -- | -113.26 | -- | 21.25 | -- |
| Kymera Therapeutics Inc | 39.21m | -311.35m | 7.05bn | 238.00 | -- | 4.45 | -- | 179.80 | -3.68 | -3.68 | 0.4642 | 19.42 | 0.0288 | -- | -- | 164,747.90 | -22.89 | -24.17 | -24.23 | -27.06 | -- | -- | -794.06 | -329.38 | -- | -- | 0.0021 | -- | -16.70 | 2.87 | -39.08 | -- | -30.75 | -- |
| Cytokinetics, Inc. | 88.04m | -784.96m | 7.48bn | 673.00 | -- | -- | -- | 84.94 | -6.53 | -6.53 | 0.733 | -5.37 | 0.0623 | -- | 5.12 | 130,815.80 | -55.55 | -49.49 | -64.23 | -55.60 | -- | -- | -891.60 | -897.66 | -- | -11.95 | 2.33 | -- | 376.56 | 9.54 | -33.15 | -- | 17.55 | -- |
| Nuvalent Inc | 0.00 | -425.38m | 7.88bn | 228.00 | -- | 6.28 | -- | -- | -5.85 | -5.85 | 0.00 | 15.96 | 0.00 | -- | -- | 0.00 | -33.30 | -27.97 | -35.31 | -29.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.13 | -- | -- | -- |
| ICON PLC | 8.10bn | 599.48m | 8.30bn | 39.80k | 14.69 | 0.8892 | 8.40 | 1.02 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Vaxcyte Inc | 0.00 | -766.63m | 8.61bn | 507.00 | -- | 2.92 | -- | -- | -5.63 | -5.63 | 0.00 | 20.49 | 0.00 | -- | -- | 0.00 | -23.54 | -24.62 | -24.86 | -26.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -65.25 | -- | 118.08 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -144.34m | 8.65bn | 18.30k | -- | 2.73 | 33.12 | 2.15 | -2.96 | -2.96 | 80.79 | 64.30 | 0.5477 | 9.04 | 5.62 | 219,419.80 | -1.94 | 3.42 | -2.28 | 4.01 | 34.98 | 36.22 | -3.54 | 6.37 | 1.02 | 3.43 | 0.3999 | 0.00 | -0.8545 | 6.55 | -1,501.75 | -- | 5.64 | -- |
| Praxis Precision Medicines Inc | 0.00 | -303.27m | 8.86bn | 168.00 | -- | 9.13 | -- | -- | -13.45 | -13.45 | 0.00 | 34.85 | 0.00 | -- | -- | 0.00 | -42.68 | -61.92 | -45.82 | -68.99 | -- | -- | -- | -9,004.13 | -- | -- | 0.00 | -- | -100.00 | -- | -65.88 | -- | -- | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 8.92bn | 3.10k | 112.28 | 4.42 | 48.53 | 7.34 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Arrowhead Pharmaceuticals Inc | 1.09bn | 202.27m | 8.98bn | 711.00 | 41.60 | 15.49 | 34.70 | 8.23 | 1.54 | 1.54 | 7.90 | 4.14 | 0.8335 | -- | 9.86 | 1,534,432.00 | 17.84 | -25.96 | 21.44 | -30.82 | -- | -- | 21.41 | -76.01 | -- | 5.91 | 0.5068 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| Tempus AI Inc | 1.27bn | -245.03m | 9.19bn | 3.80k | -- | 18.65 | -- | 7.23 | -1.41 | -1.41 | 7.30 | 2.76 | 0.7946 | 10.52 | 5.46 | 334,681.30 | -15.31 | -41.14 | -19.31 | -55.06 | 62.74 | 54.59 | -19.27 | -55.73 | 3.00 | -3.90 | 0.7161 | -- | 83.41 | 46.57 | 67.17 | -- | 15.24 | -- |
Data as of Mar 04 2026. Currency figures normalised to Cytokinetics Inc's reporting currency: US Dollar USD
63.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2025 | 17.72m | 14.49% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 13.99m | 11.44% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.09m | 9.07% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 9.46m | 7.74% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 7.58m | 6.20% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 5.83m | 4.76% |
| FIAM LLCas of 31 Dec 2025 | 3.34m | 2.73% |
| Deep Track Capital LPas of 31 Dec 2025 | 3.34m | 2.73% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.06m | 2.50% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 2.76m | 2.26% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
